Clinical Cancer Research Landon Prizes for Basic and Translational Cancer Research Tumor Immunology: New Perspectives
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online
This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Tomlinson, J.
Right arrow Articles by Nguyen, M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Tomlinson, J.
Right arrow Articles by Nguyen, M.
Clinical Cancer Research Vol. 5, 3516-3522, November 1999
© 1999 American Association for Cancer Research

Molecular Oncology, Markers, Clinical Correlates

Different Patterns of Angiogenesis in Sarcomas and Carcinomas1

James Tomlinson, Sanford H. Barsky, Scott Nelson, Samuel Singer, Behnaz Pezeshki, Maggie C. Lee, Frederick Eilber and Mai Nguyen2

Departments of Surgery [J. T., B. P., M. C. L., F. E., M. N.] and Pathology [S. H. B., S. N.], University of California, Los Angeles, California 90095-1782, and Department of Surgery, Harvard Medical School, Boston, Massachusetts 02115 [S. S.],3


   ABSTRACT
Top
 ABSTRACT
INTRODUCTION
 MATERIALS AND METHODS
 RESULTS
 DISCUSSION
 REFERENCES
 
Solid tumors depend on angiogenesis for growth and metastasis. It has been shown that blood vessel density, as determined by counting the number of capillaries in clustered bursts, is a significant prognostic factor in carcinomas. It is unclear, however, whether vessel density is a prognostic factor in sarcomas. In this study, we examined angiogenesis in sarcomas of various grades and compared their vascular patterns to those of carcinomas. Microvessels were identified by von Willebrand factor staining. The matrix of multiple sarcoma and breast carcinoma specimens were extracted and subjected to Western analysis of various angiogenic factors and inhibitors. Metalloproteinase inhibitor presence was also determined by in situ hybridization. In breast carcinomas, capillaries were clustered in bursts within the stroma of the tumor, whereas the sarcoma capillaries were homogeneously distributed in the tumor stroma. Random blood vessel density per high power field in sarcomas did not correlate with patient prognosis. The matrix of sarcomas and carcinomas contained both angiogenic stimulators and inhibitors. Tissue inhibitor of metalloproteinase-1 was found predominantly in fibroblasts and myofibroblasts in the matrix of carcinoma specimens. The difference in the pattern of angiogenesis in sarcomas and carcinomas may be attributable to the presence of fibroblasts and myofibroblasts in carcinomas, resulting in the compartmentalization of bursts of angiogenic factors. The homogeneous appearance of vessel density in sarcomas observed in the present study would be the consequence of the influence of a single compartment.


   INTRODUCTION
Top
 ABSTRACT
 INTRODUCTION
MATERIALS AND METHODS
 RESULTS
 DISCUSSION
 REFERENCES
 
The growth and metastasis of solid tumors are dependent on their ability to initiate and sustain new capillary growth, i.e., angiogenesis (1) . This hypothesis is supported by multiple animal experiments in which tumors implanted in chicks, rodents, and rabbits are restricted in growth during the avascular phase, but rapid growth and metastasis occur shortly after vascularization. In addition, angiogenesis inhibitors that are not cytostatic to tumor cells in vitro inhibit tumor growth and metastasis in the animals in vivo (2) . Clinical observations in human cancer have added support to the hypothesis that tumors are angiogenesis dependent. The levels of various angiogenic factors in bodily fluids have been demonstrated to correlate with prognosis in cancer patients (3) . Multiple agents have been developed to inhibit this phenomenon of tumor-induced angiogenesis (4) . Many of these agents have completed Phase I and Phase II clinical trials and are presently in the midst of Phase III trials.

Another application of angiogenesis research, as determined by the amount of vascularity in the tumor specimen, was first shown to have prognostic significance in breast cancer by Weidner et al. (5) in 1991. The number of vessels in a tumor specimen correlates with the disease stage and can add prognostic prediction independent of other routinely used markers. Since 1991, an overwhelming majority of published reports have shown a significant correlation between the density of intratumoral microvessels of invasive breast carcinoma and the incidence of metastases and/or patient survival. Similar associations have now been reported for patients with gastrointestinal carcinoma, melanoma, prostate carcinoma, testicular carcinoma, ovarian carcinoma, bladder carcinoma, central nervous system tumors, multiple myeloma, non-small cell lung carcinoma, and squamous carcinoma of the head and neck (6) .

Although vascular density has been prognostic in carcinomas, two recent reports showed that microvessel counts in sarcomas do not correlate with patient outcome (7 , 8) . We therefore set out to investigate whether microvessel count correlates with clinical outcome in our patient population with soft tissue sarcomas.


   MATERIALS AND METHODS
Top
 ABSTRACT
 INTRODUCTION
 MATERIALS AND METHODS
RESULTS
 DISCUSSION
 REFERENCES
 
Patient Population.
From the group of patients with soft tissue sarcomas treated at the University of California, Los Angeles Medical Center between 1984 and 1995, we chose 25 cases in which we had access to tissue prior to any treatment modality including surgery, radiation, and chemotherapy. There were 19 patients with leiomyosarcoma and six with malignant fibrous histiocytoma. Median follow-up was 35 months, with a range from one month to 12 years. One patient was lost to follow-up. Metastases included disease in remote organs, such as lung or liver. Disease-specific survival reflected death from tumor-related causes. Information was obtained from review of the patients’ medical records and verbal contact with the patients’ primary physicians.

Immunohistochemistry.
The specimens were obtained from archival paraffin-embedded tissues of the above 25 patients as well as from selected cases of breast carcinoma. Sections (5 µm) were cut, and H&E preparations of each specimen were performed to confirm the presence of nonnecrotic tumor. Immunostaining was performed with an avidin-biotin-peroxidase complex technique (9) . The slides were sequentially incubated at room temperature as follows: (a) in 0.3% H2O2 to block the endogenous peroxidase activity; (b) in 5% serum to block nonspecific antibody binding; (c) with the specific primary antibody overnight; (d) with the secondary antibody; (e) with avidin and biotinylated horseradish peroxidase (Vector, Burlingame, CA); and (f) with 3,3'-diaminobenzidine and H2O2 (Vector). The tissues were then stained with Gill’s hematoxylin and NH4OH, dehydrated, and mounted. The rabbit antihuman vWf4 antibody was purchased from Dako (Carpinteria, CA) and used at 1 µg/ml. Negative controls included staining with mouse IgG1 (Becton Dickinson, San Jose, CA). Secondary antibodies were used at 1:200 dilution and included biotinylated antimouse IgG made in horse and biotinylated antirabbit IgG made in goat (Vector).

Positively stained vessels were counted in five separate fields for each specimen using an Olympus model BH2 microscope. In keeping with the protocol developed by Weidner et al. (5) , fields containing the highest density of vWf-positive vessels, i.e., "bursts," were identified at scanning power and then counted at x400. The numbers for the five fields were averaged. However, the vessel counts used to calculate the SD values depicted in Fig. 3Citation were obtained from 10 representative fields of the tumor specimen, which would include both "bursts" as well as areas with sparse vessels. Fig. 3Citation represents the SD in individual cases averaged together.



View larger version (30K):
[in this window]
[in a new window]
  		Fig. 3. Vessel count variation per microscopic field.

 
Statistical Analysis.
Descriptive statistics, such as mean and SD, were used to summarize the results. The {chi}2 and Wilcoxon tests were used for univariate analysis. Statistical significance was defined by P < 0.05.

Western Analysis of Tumor Matrix.
Five sarcoma and five breast carcinoma specimens were used for matrix extraction according to a protocol described previously (10) . These specimens were obtained either fresh or fresh frozen. Briefly, the tissue fragments were pelleted and homogenized in ~3 volumes of high salt extraction buffer (3.5 M NaCl and 50 mM Tris-HCl, pH 7.4) containing proteinase inhibitors. The homogenate was centrifuged at 12,000 x g for 15 min, and the high salt extraction was repeated. The insoluble material was again pelleted and extracted overnight in an equivalent volume of 2 M urea, 50 mM Tris-HCl buffer (pH 7.4) with constant stirring. The urea extract was centrifuged at 12,000 x g for 15 min, and the supernatant was dialyzed against several changes of Tris-buffered saline (TBS; 150 mM NaCl, 50 mM Tris-HCl, pH 7.4) containing proteinase inhibitors. High salt extracts were also dialyzed against TBS. Proteins in the media were precipitated overnight at 4°C with ammonium sulfate at 50% saturation. The precipitate was collected by centrifugation at 10,000 x g for 1 h and dissolved in 1 ml of TBS with proteinase inhibitors. The high salt and urea extracts and the media fractions were stored at -80°C.

Subsequently, the protein contents were measured and normalized for Western analysis. Tissue extracts were resolved on nonreducing SDS-PAGE mini-gels and transferred to nitrocellulose membranes by electrophoretic blotting. Membranes were blocked for 2 h at room temperature in PBS-Tween (PBS and 0.1% Tween 20) containing 1% BSA and 1% gelatin and then incubated for 1 h with primary antibody in PBS-Tween. The primary antibodies used were against VEGF, bFGF, aFGF, TGF-{beta}, TGF-{alpha}, PD-ECGF, angiogenin, and IFN-{alpha} obtained from R&D (Minneapolis, MN). Other sources were used for the antibodies to TIMP-1 (Chemicon, Temecula, CA), thrombospondin (Dr. Luisa Iruela Arispe, UCLA), and plasminogen fragment (American Diagnostica, Inc., Greenwich, CT). The concentration of these primary antibodies was 1 µg/ml. Membranes were then washed three times over a 30-min period in PBS-Tween, incubated for 1 h with the appropriate horseradish peroxidase-conjugated secondary antibody (mouse monoclonal antirabbit IgG or sheep antimouse IgG; Amersham, Piscataway, NJ) diluted 1:5000 in PBS-Tween, and washed in PBS-Tween as before. The membranes were then developed using the ECL Western blotting detection system according to the manufacturer’s instructions (Amersham).

In Situ Hybridization.
In situ hybridization studies were conducted with riboprobes made from the full-length TIMP-1 cDNA (provided by Dr. Judith Gasson, UCLA). The pBluescript SK plasmid (Stratagene, La Jolla, CA) containing a 0.5-kb EcoRI fragment of the human TIMP-1 gene was linearized with XbaI for antisense strand preparation from the T7 promoter and with HindIII for sense strand preparation from the T3 promoter (11) . [35S]UTP-labeled RNA transcripts were synthesized at concentrations of 4 to 6 x 105 cpm/µl. Paraffin-embedded sections were deparaffinized, fixed in 4% paraformaldehyde in PBS, rehydrated, washed in 0.5x SSC, and digested with proteinase K at room temperature for 10 min. The sections were acetylated using 0.25% acetic anhydride and 0.1 M triethanolamine HCl rinsed with 0.5x SSC and dehydrated with ethanol and finally dried. A TIMP-1 riboprobe was applied in a hybridization mixture containing deionized formamide (50%), dextran sulfate (10%), tRNA (0.5 mg/l), salmon sperm DNA (1 mg/ml), 10 mM DTT, 0.3 M NaCl, 5 mM EDTA, 20 mM Tris-HCl, and 10 mM NaPO4 (pH 6.8). The mixture was heated at 65°C for 15 min and chilled on ice. Fresh DTT was added to achieve a concentration of 20 mM. Then 120 µl of the mixture were applied to each section, and Parafilm coverslips were applied. Hybridizations were carried out in humidified chambers overnight at 55°C. Coverslips were removed in 5x SSC, 10 mM DTT at 55°C. Sections were washed with 2x SSC containing 2-mercaptoethanol and EDTA, treated with RNase A, and washed in 0.1x SSC at 62°C for 3 h (high stringency). Slides were then washed for 5 min at room temperature in 0.5x SSC without 2-mercaptoethanol or EDTA. The sections were dehydrated with ethanol and air dried. The slides were exposed to Ilford K5D emulsion and stored in the dark at 4°C until developed, which took at least 10–14 days. Digital image analysis was then used to compare the signal intensities with the antisense probe with the signal intensities of the sense probe (background) over the corresponding areas of tumor cells and stroma in the carcinomas. Digital image analysis was composed of a Leitz Dialux microscope linked to a Vidicon camera, an IBM PC with PCVision digitizer, and Microscience software.


   RESULTS
Top
 ABSTRACT
 INTRODUCTION
 MATERIALS AND METHODS
 RESULTS
DISCUSSION
 REFERENCES
 
Clinical and Statistical Analysis.
The sarcomas were assigned histological grades including low, moderate, and high. We found that the histological grade of the tumor correlated with survival (P = 0.03) but not with metastases (Fig. 1)Citation . The vessel counts ranged from 10 to 110 per high power field. For purposes of analysis, the cases were divided into three groups: 1–29, 30–59, and >=60 vessel count/field. There was no correlation found between metastatic disease (present and future) or survival and the number of "burst" vessels stained by vWf (Fig. 2)Citation . When all representative microscopic fields were taken into account, we found that there was a larger SD among the vessel counts of 10 breast carcinoma cases than in those of the present 25 cases (Fig. 3)Citation .



View larger version (28K):
[in this window]
[in a new window]
  		Fig. 1. Follow-up metastatic disease (A) and death (B) in relation to histological grade of sarcomas. Interval follow-up was similar in the different groups.

 


View larger version (21K):
[in this window]
[in a new window]
  		Fig. 2. Current metastatic disease (A), follow-up metastatic disease (B), and follow-up death (C) in relation to vessel count in progressive increments in sarcomas. Interval follow-up was similar in the different groups.

 
Vessel Patterns.
At scanning power, we observed that the vessels in sarcomas were in general more diffusely distributed, whereas those in breast carcinomas would often cluster in "bursts" (Fig. 4)Citation . In carcinomas, malignant cells were juxtaposed to stromal cells including fibroblasts and myofibroblasts (Fig. 5)Citation . In contrast, the sarcoma specimens contained mainly malignant cells with a relatively acellular matrix.



View larger version (71K):
[in this window]
[in a new window]
  		Fig. 4. Immunohistochemical staining of leiomyosarcoma (A) and breast carcinoma (B) with vWf. x400.

 


View larger version (76K):
[in this window]
[in a new window]
  		Fig. 5. H&E staining of sarcoma (A) and breast carcinoma (B).

 
Tumor Matrix Analysis.
We used Western blotting to analyze the extracted matrix from five representative leiomyosarcomas and five breast carcinoma cases (Table 1)Citation . The sarcoma matrix contained VEGF, bFGF, aFGF, TGF-{beta}, PD-ECGF, angiogenin, and TIMP-1. The carcinoma matrix contained VEGF, TGF-{alpha}, PD-ECGF, angiogenin, and TIMP-1. Overall, there were no significant differences in the angiogenic profile of the soluble matrix components of sarcomas and carcinomas.


View this table:
[in this window]
[in a new window]
  		Table 1 Western analysis of the matrix of sarcoma and breast carcinoma

 
In in situ hybridization studies with the antisense TIMP-1 probe, strong signals were observed corresponding to TIMP-1 expression within the stromal cells of the carcinomas (Fig. 6)Citation . The TIMP-1 signal was observed only within the stromal cells and not the carcinoma cells. Furthermore, there was a gradient of TIMP-1 expression being more greatly expressed within the stromal cells near the invading carcinoma cells. Signal intensities with the antisense TIMP-1 probe were 5–10-fold greater than those with the sense probe (background; Fig. 7Citation ).



View larger version (37K):
[in this window]
[in a new window]
  		Fig. 6. Schematic of the compartments in sarcomas and carcinomas.

 


View larger version (172K):
[in this window]
[in a new window]
  		Fig. 7. In situ hybridization of TIMP-1 (A) and H&E staining in breast carcinoma (B). The TIMP-1 signal was observed only within the stromal cells and not the carcinoma cells.

 

   DISCUSSION
Top
 ABSTRACT
 INTRODUCTION
 MATERIALS AND METHODS
 RESULTS
 DISCUSSION
REFERENCES
 
In the present study, we have statistically analyzed a group of our sarcoma patient population for any correlation between vessel count and clinical outcome. This small group of patients was carefully chosen, because the tissues were obtained prior to any treatments such as surgery, radiation, and chemotherapy. The data here did confirm the importance of grade as a prognostic indicator in sarcomas. However, neovascularity, as determined by counting bursts of vessels stained with vWf antibody, had no prognostic significance. This conclusion is in agreement with two studies published previously of sarcoma patients. Ohsawa et al. (7) saw no correlation in 42 cases of malignant fibrous histiocytoma in Japan, and Saenz et al. (8) discovered the same result in 119 cases of soft tissue sarcomas at the Memorial Sloan-Kettering Cancer Center. We are confident that we adhered to the techniques described previously by Weidner et al. (5) . We had used this technique successfully in the past to study a group of breast carcinoma cases and had at that time found a correlation between vessel count and known prognostic indicators (9) . Recently, Kumar et al. (12) reported that the antibody to CD105, which preferentially reacts with endothelial cells in angiogenic tissues, is more accurate than a pan-endothelial marker such as CD34. Although vWf antibody does not distinguish between tumor neovascularization from preexisting vessels, it has been used successfully by Weidner and many other investigators, including ourselves, in the past to stain a vast number of human carcinoma types.

Ohsawa et al. (7) concluded that "angiogenesis is apparently not a key factor in the formation of metastasis by sarcomas." We do not equate lack of prognostic significance to lack of functional importance. In fact, much evidence suggests that sarcomas are angiogenesis dependent. Sarcomas are known to express potent angiogenic factors (13 , 14) . In animal models of rhabdomyosarcoma, an antiangiogenic drug, TNP-470, inhibited tumor growth (15) . Preliminary results from human clinical trials with various antiangiogenic drugs suggested that suppression of neovascularization can also stop tumor growth in patients with sarcomas. There was objective response when TNP-470 was given to patients with Kaposi’s sarcoma (16 , 17) . Similar promising results were observed with other antiangiogenic drugs including thalidomide, pentosan polysulfate, tecogalan, suramin, and platelet factor-4 (18, 19, 20, 21, 22) .

In the process of determining vascular density for this study, we have observed that the pattern of blood vessel distribution is different in the sarcoma specimens than in the carcinoma specimens. Whereas the carcinoma vessels often cluster in "bursts," the sarcoma vessels are more homogeneously and diffusely distributed. This is manifested in the larger SD of vessel counts in the typical carcinoma specimen. In carcinomas, the vessels are in general found in the stroma adjacent to the infiltrative tumor. On the other hand, the sarcoma vessels are often seen inside the tumor mass.

Carcinomas are composed of two compartments: an epithelial compartment of malignant epithelial cells and a stromal compartment of fibroblasts and myofibroblasts. This desmoplastic benign stroma can account for 30–90% of the specimens. Both compartments contribute to the tumoral matrix in terms of their respective gene products. Sarcomas, on the other hand, are composed of predominantly only one compartment, the malignant mesenchymal cell that largely synthesizes the sarcoma matrix and contributes mostly to its gene products. Although sarcomas also contain a benign stromal part, this component is often observed to be <1% of the specimens. Therefore, the single predominant compartment in sarcomas is comprised of the malignant mesenchymal cells.

Angiogenesis is thought to be regulated by the balance of positive and negative factors in a particular microenvironment. The Western analysis performed showed that the stroma of the two tumor types contained both angiogenic stimulators and inhibitors. However, in situ hybridization with one angiogenic inhibitor, TIMP-1 (23) , showed that it localized predominantly to the stromal fibroblasts and myofibroblasts and not within the carcinoma cells. In carcinomas, two compartments contribute to this balance. Angiogenesis may occur when the influence of one compartment exceeds the other. In areas near the malignant epithelial cells, angiogenic stimulation predominates and results in "bursts" of vessels. On the other hand, the region near the stromal fibroblasts and myofibroblasts would contain more angiogenic inhibitors and would be less vascular. Angiogenesis thus becomes an all-or-none phenomenon, dependent upon the contributions of both compartments. Classic clustered bursts of angiogenesis in carcinoma are thus the example of this phenomenon. Sarcomas, on the other hand, are governed predominantly by the contributions of a single compartment, the sarcomal cells themselves. Hence, their contribution would be more constitutive, stable, and predictable and not confused by the presence of another compartment. The diffuse vessel density of sarcomas that we have observed in the present study would be the consequence of the influence of a single compartment.


   ACKNOWLEDGMENTS
 
We thank Dr. Hejing Wang from the UCLA Department of Mathematics for statistical analysis.


   FOOTNOTES
 
The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked advertisement in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

1 Supported by NIH Grant CA69433 and grants from the American Cancer Society and the UCLA Jonsson Comprehensive Cancer Center. J. T. is a recipient of a National Research Service Award. Back

2 To whom requests for reprints should be addressed, at UCLA Surgery/Oncology, Box 951782, Los Angeles, CA 90095-1782. Phone: (310) 206-2215; Fax: (310) 825-7575. Back

3 Research was performed at the University of California Los Angeles Medical Center, Los Angeles, CA 90095. Back

4 The abbreviations used are: vWf, von Willebrand factor; VEGF, vascular endothelial growth factor; bFGF, basic fibroblast growth factor; aFGF, acidic FGF; TGF, transforming growth factor; PD-ECGF, platelet-derived endothelial cell growth factor; TIMP, tissue inhibitor of metalloproteinase. Back

Received 5/12/99; revised 8/17/99; accepted 8/20/99.


   REFERENCES
Top
 ABSTRACT
 INTRODUCTION
 MATERIALS AND METHODS
 RESULTS
 DISCUSSION
 REFERENCES
 

  1. Folkman J. Angiogenesis in cancer, vascular, rheumatoid and other disease. Nat. Med., 1: 27-31, 1995.[Medline]
  2. Folkman J. Clinical applications of research on angiogenesis. N. Engl. J. Med., 333: 1757-1763, 1995.[Free Full Text]
  3. Nguyen M. Angiogenic factors as tumor markers. Investig. New Drugs, 15: 29-37, 1997.[Medline]
  4. Lee M. C., Tomlinson J., Nguyen M. Lessons from clinical trials of anti-angiogenic drugs in the treatment of cancer Mousa S. eds. . Angiogenesis Inhibitors and Stimulators: Therapeutic Implications, in press., : Landes Bioscience Georgetown, TX 1999.
  5. Weidner N., Semple J. P., Welch W. R., Folkman J. Tumor angiogenesis and metastasis: correlation in invasive breast carcinoma. N. Engl. J. Med., 324: 1-8, 1991.[Abstract]
  6. Weidner N., Folkman J. Tumoral vascularity as a prognostic factor in cancer. Imp. Adv. Oncol., : 167-190, 1996.
  7. Ohsawa M., Tomita Y., Kuratsu S., Kanno H., Aozasa K. Angiogenesis in malignant fibrous histiocytoma. Oncology, 52: 51-54, 1995.[Medline]
  8. Saenz N. C., Heslin M. J., Adsay V., Lewis J. J., Leung D. H., LaQuaglia M. P., Brennan M. F. Neovascularity and clinical outcome in high-grade extremity soft tissue sarcomas. Ann. Surg. Oncol., 5: 48-53, 1998.[Abstract]
  9. Nguyen M., Corless C. L., Kraling B. M., Tran C., Atha T., Bischoff J., Barsky S. H. Vascular expression of E-selectin is increased in estrogen-receptor-negative breast cancer. Am. J. Pathol., 150: 1307-1314, 1997.[Abstract]
  10. Sternlicht M. D., Safarians S., Rivera S. P., Barsky S. H. Characterizations of the extracellular matrix and proteinase inhibitor content of human myoepithelial tumors. Lab. Investig., 74: 781-796, 1996.[Medline]
  11. O’Connell J. T., Shao Z., Drori B. S., Basbaum C. B., Barsky S. H. Altered mucin expression is a field change that accompanies mucinous (colloid) breast carcinoma histogenesis. Hum. Pathol., 29: 1517-1523, 1998.[Medline]
  12. Kumar S., Ghellal A., Li C., Byrne G., Haboubi N., Wang J. M., Bundred N. Breast carcinoma: vascular density determined using CD105 antibody correlates with tumor prognosis. Cancer Res., 59: 856-861, 1999.[Abstract/Free Full Text]
  13. Brown L. F., Tognazzi K., Dvorak H. F., Harrist T. J. Strong expression of kinase insert domain-containing receptor, a vascular permeability factor/vascular endothelial growth factor receptor in AIDS-associated Kaposi’s sarcoma and cutaneous angiosarcoma. Am. J. Pathol., 148: 1065-1074, 1996.[Abstract]
  14. Salvin P., Lymboussaki A., Heikkila P., Jasskela-Saari H., Enholm B., Aase K., von Euler G., Eriksson U., Alitalo K., Joensuu H. Vascular endothelial growth factors VEGF-B and VEGF-C are expressed in human tumors. Am. J. Pathol., 153: 103-108, 1998.[Abstract/Free Full Text]
  15. Kalebic T., Tsokos M., Helman L. J. Suppression of rhabdomyosarcoma growth by fumagillin analog TNP-470. Int. J. Cancer, 68: 596-599, 1996.[Medline]
  16. Dezube B., Von Roenn J. H., Holden-Wiltse J., Cheung T. W., Remick S. C., Cooley T. P., Moore J., Sommadossi J. P., Shriver S. L., Suckow C. W., Gill P. S. Fumagillin analog in the treatment of Kaposi’s sarcoma: a Phase I AIDS clinical trial group study. J. Clin. Oncol., 16: 1444-1449, 1998.[Abstract/Free Full Text]
  17. Pluda J. M., Wyvill K. K., Lietzau J., Figg W. D., Whitcup S. M., Feigal E., Humphrey R., Welles L., Yarchoan R. A phase I trial administering the angiogenesis inhibitor TNP-470 (AGM-1470) to patients with HIV-associated Kaposi’s Sarcoma (KS). Natl. AIDS Malign. Conf., A19: 1996.
  18. Bower M., Howard M., Gracie F., Phillips R., Fife K. A Phase II study of thalidomide for Kaposi’s sarcoma activity and correlation with KSHV DNA load. Natl. AIDS Malign. Conf., A35: 76a 1996.
  19. Pluda J. M., Shay L. E., Tannenbaum S., Cohen P. J., Goldspiel B. R., Adamo D., Cooper M. R., Broder S., Yarchoan R. Administration of pentosan polysulfate to patients with human immunodeficiency virus-associated Kaposi’s sarcoma. J. Natl. Cancer Inst., 85: 1585-1592, 1993.[Abstract/Free Full Text]
  20. Tulpule A., Snyder J. C., Espina B. M., Higashi L., Satomi M., Lombardy E. E., Gill P. S. A Phase I study of Tecogalan, a novel angiogenesis inhibitor in the treatment of AIDS-related Kaposi’s sarcoma and solid tumors. Blood, 84: A248 1994.
  21. Kobayashi K., Vokes E. E., Vogelzang N. J., Jarisch L., Soliven B., Ratain M. J. Phase I study of suramin given by intermittent infusion without adaptive control in patients with advanced cancer. J. Clin. Oncol., 13: 2196-2207, 1995.[Abstract/Free Full Text]
  22. Northfelt D. W., Robles R., Lang W., Wagner B., Kahn J., Bonnem E. Phase I/II study of intravenous (IV) recombinant platelet factor 4 (rPF4) in AIDS-related Kaposi’s Sarcoma (KS). Proc. Am. Soc. Clin. Oncol., 14: 288 1995.
  23. Wojtowicz-Praga S. M., Dickson R. B., Hawkins M. J. Matrix metalloproteinase inhibitors. Invest. New Drugs, 15: 61-75, 1997.[Medline]



This article has been cited by other articles:


Home page
 Clin. Chem.Home page
A. M. Sieuwerts, P. A. Usher, M. E. Meijer-van Gelder, M. Timmermans, J. W.M. Martens, N. Brunner, J. G.M. Klijn, H. Offenberg, and J. A. Foekens
Concentrations of TIMP1 mRNA Splice Variants and TIMP-1 Protein Are Differentially Associated with Prognosis in Primary Breast Cancer
Clin. Chem., July 1, 2007; 53(7): 1280 - 1288.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
J. Ahlen, J. Wejde, O. Brosjo, A. von Rosen, W.-H. Weng, L. Girnita, O. Larsson, and C. Larsson
Insulin-Like Growth Factor Type 1 Receptor Expression Correlates to Good Prognosis in Highly Malignant Soft Tissue Sarcoma
Clin. Cancer Res., January 1, 2005; 11(1): 206 - 216.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
J. V. Heymach, J. Desai, J. Manola, D. W. Davis, D. J. McConkey, D. Harmon, D. P. Ryan, G. Goss, T. Quigley, A. D. Van den Abbeele, et al.
Phase II Study of the Antiangiogenic Agent SU5416 in Patients with Advanced Soft Tissue Sarcomas
Clin. Cancer Res., September 1, 2004; 10(17): 5732 - 5740.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
L. Zhang, R. S. Maul, J. Rao, S. Apple, D. Seligson, M. Sartippour, R. Rubio, and M. N. Brooks
Expression Pattern of the Novel Gene EG-1 in Cancer
Clin. Cancer Res., May 15, 2004; 10(10): 3504 - 3508.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
D. Huang, J. L. Rutkowski, G. M. Brodeur, P. M. Chou, J. L. Kwiatkowski, A. Babbo, and S. L. Cohn
Schwann Cell-conditioned Medium Inhibits Angiogenesis
Cancer Res., November 1, 2000; 60(21): 5966 - 5971.
[Abstract] [Full Text]

This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Tomlinson, J.
Right arrow Articles by Nguyen, M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Tomlinson, J.
Right arrow Articles by Nguyen, M.

HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online